Quick Hits

Chronic hepatitis C is the most common cause of hepatocellular carcinoma (HCC) in the United States and Europe. Antiviral therapy against hepatitis C virus (HCV) has long been regarded as one of the most effective chemopreventive strategies for HCC. Sustained viral response (SVR) in patients without cirrhosis can halt disease progression, thereby decreasing the risk […]

Quick Hits

In 2018, there is substantial evidence that hepatitis C virus (HCV) infection is a systemic disease associated with adverse clinical, economic, and patient-reported outcomes (PROs). Specifically, the clinical consequences of HCV infection can lead to both hepatic and extrahepatic manifestations. In this context, HCV infection increases the risk of liver-related and overall mortality. Additionally, HCV […]

Quick Hits

Chronic hepatitis C infection (HCV) is a major public health problem affecting more than 71 million patients worldwide including more than 3.5 million patients in the United States.1 With the introduction of direct acting antiviral agents (DAAs), it is now possible to cure hepatitis C infection even in patients with advanced fibrosis, cirrhosis and HCV […]

Quick Hits

Epidemiology. Recent data from the U.S. Cancer Statistics registry show that hepatocellular carcinoma (HCC) continues to rise albeit at a slower rate recently (4.5 percent increase annually from 2000 to 2009, and 0.7 percent from 2010 to 2012). Men between 55 and 64 years of age, Hispanics and, at state-level, Texans, are the most commonly […]

Quick Hits

Over 240 million people in the world are chronically infected with hepatitis B virus (HBV). In many infected individuals, initial infection leads to clearance (defined as the loss of surface antigen [HBsAg]). Some HBsAg negative individuals remain HBV DNA positive (i.e., occult HBV) and others have HBV DNA in the liver but are serologically cleared. […]

Quick Hits

Combination direct-acting antiviral (DAA) therapy of eight to 24 weeks for the treatment of chronic hepatitis C is highly effective. Current guidelines do not encourage treatment for less than 12 weeks. However, mounting evidence indicates that many patients can achieve sustained virologic response (SVR) with only eight weeks of treatment. Thus, treatment for shorter durations […]

Quick Hits

The advent of direct acting antivirals (DAAs) in the treatment of chronic hepatitis C infection has been revolutionary in that they have drastically mitigated the side effects of therapy while enhancing efficacy relative to interferon-based therapy. DAAs are broadly categorized into the NS3/4A protease inhibitors, NS5A inhibitors, and the non-nucleoside and nucleotide NS5B inhibitors. Ribavirin, […]

Quick Hits

Evidence from a few randomized trials and multiple observational studies supports performing a liver ultrasound every six months as part of hepatocellular carcinoma (HCC) surveillance in patients with hepatitis C virus-related cirrhosis (HCVc). Although the possibility of using other technical modalities is tempting, there are concerns regarding radiation exposure and cost. Use of multiphase computed […]